The object of this review is to gather and summarise published studies of the MET gene in myeloid malignancies, and to provide evidence that drugs currently used in solid tumours to block the HGF/Met axis should also be considered for the therapy of chronic myeloid malignancies. The gene discussed is MET; the disease is myeloid neoplasm.